Predictors of Poor Response to Salvage Chemotherapy in Relapsed/ Refractory Pediatric Hodgkin Lymphoma- A Retrospective Analysis from Tertiary Cancer Centre in India

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
Predictors of Poor Response to Salvage Chemotherapy in Relapsed/ Refractory Pediatric Hodgkin Lymphoma- A Retrospective Analysis from Tertiary Cancer Centre in India ; volume:54 ; number:03 ; year:2018 ; pages:160-170
Annals of National Academy of Medical Sciences (India) ; 54, Heft 03 (2018), 160-170

Beteiligte Personen und Organisationen
Bhethanabhotla, Sainath
Vishnubhatla, Sreenivas
Bakhshi, Sameer

DOI
10.1055/s-0040-1712842
URN
urn:nbn:de:101:1-2020070908225231925697
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
2025-08-14T11:02:14+0200

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Bhethanabhotla, Sainath
  • Vishnubhatla, Sreenivas
  • Bakhshi, Sameer

Ähnliche Objekte (12)

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi

Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy

Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach

Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway

Verbundene Objekte